Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 167 • 2020 Pediatric Rheumatology Symposium
Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
Melissa Elder ¹, Luciana Paim marques², Akaluck Thatayatikom ¹, John Bowden ², Bianca da SIlva ² and Juan Aristizabal ², ¹University of Florida, Gainesville, ²University of Florida, Gainesville, Florida
Background/Purpose: Metabolomic and lipidomic pathways serve as key sensors and effectors of genetic, epigenetic, and environmental factors that shape the development and function of the…
Abstract Number: 022 • 2020 Pediatric Rheumatology Symposium
Association of Plasma Metabolomic Profiles with Methotrexate Response in Juvenile Idiopathic Arthritis
Ryan Funk¹ and Mara Becker ², ¹University of Kansas, Leawood, Kansas, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill
Background/Purpose: Despite efforts to identify biomarkers to guide therapy in the treatment of juvenile idiopathic arthritis (JIA), drug therapy remains a trial-and-error process. In the…
Abstract Number: 101 • 2020 Pediatric Rheumatology Symposium
Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond
Mona Riskalla¹, Fatima Barbar-Smiley ², Michael Shyne ¹ and Melissa Lerman ³, ¹University of Minnesota, Minneapolis, Minnesota, ²Nationwide Children's Hospital, Columbus, Ohio, ³Philadelphia, Pennsylvania
Background/Purpose: Uveitis associated with JIA (JIA-U) is the most common extra-articular complication of JIA. As JIA-U is associated with significant risk of visual loss and…
Abstract Number: 171 • 2020 Pediatric Rheumatology Symposium
Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis
Kelsey Chomistek¹, Cheryl Barnabe ², Katie Birnie ³, Julia Brooks ⁴, Tracey Clancy ⁵, Syeda Farwa Naqvi ⁵, Nadia Luca ⁵, Maggie Mercer ⁴, Maria Santana ⁵, Jennifer Stinson ⁶, Aynsley Wennberg ⁴ and Heinrike Schmeling ⁷, ¹Calgary, Alberta, Canada, ²University of Calgary, Calgary, Alberta, Canada, ³Alberta Children's Hospital, Calgary, Canada, ⁴Alberta Children's Hospital, Calgary, Alberta, Canada, ⁵University of Calgary, Calgary, Canada, ⁶University of Toronto & The Hospital for Sick Children, Toronto, Ontario, Canada, ⁷Alberta Children's Hospital/University of Calgary, Calgary, Alberta, Canada
Background/Purpose: Needs assessments have revealed an urgent need for disease information, self-management skills, and peer support for patients with juvenile idiopathic arthritis (JIA). Our aim…
Abstract Number: 029 • 2020 Pediatric Rheumatology Symposium
Comparison of Efficacy Between Triamcinolone Acetonide and Hexacetonide Intra-articular Treatment for Clinical Remission in Juvenile Idiopathic Arthritis
Angela Chun¹, Lutfiyya Muhammad ² and Deirdre De Ranieri ³, ¹Lurie Children's Hospital, Chicago, Iowa, ²Northwestern University Feinberg School of Medicine, Chicago, ³Lurie Children's Hospital, Chicago, Illinois
Background/Purpose: The use of intra-articular corticosteroid (IAC) injections for Juvenile Idiopathic Arthritis (JIA) was extrapolated from its use in adult inflammatory joint diseases to achieve…
Abstract Number: 107 • 2020 Pediatric Rheumatology Symposium
Defining the Prevalence of Depression and Anxiety Symptoms in Adolescents with Juvenile Idiopathic Arthritis
Lydia Li¹, Mehveen Merchant ², Shelina Gordon ³, David Lovas ⁴, Joanne Gillespie ⁴, Adam Huber ⁵, Bianca Lang ⁶, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Canada, ²Calgary, Canada, ³IWK Health Centre, Halifax, ⁴IWK Health Centre, Halifax, Canada, ⁵IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ⁶Dalhousie University - Halifax, Halifax, Canada
Background/Purpose: We aimed to evaluate the prevalence of depressive and/or anxiety symptoms in adolescents with juvenile idiopathic arthritis (JIA) and explore the association with demographic…
Abstract Number: 175 • 2020 Pediatric Rheumatology Symposium
Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration
Erin Balay¹, Jennifer Weiss ², Y. Ingrid Goh ³, Nathan Rubin ⁴ and Danielle Bullock ⁴, ¹University of Minnesota, saint paul, ²Hackensack University Medical Center, Hackensack, ³The Hospital for Sick Children, Toronto, Canada, ⁴University of Minnesota, Minneapolis
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood disease which can result in debilitating arthritis. The 2011 ACR JIA treatment guidelines recommend intra-articular corticosteroid…
Abstract Number: 030 • 2020 Pediatric Rheumatology Symposium
The Efficacy and Safety of Intraarticular Injection of Triamcinolone Acetonide versus Triamcinolone Hexacetonide in the Treatment of Juvenile Idiopathic Arthritis
Shiri Rubin ¹, Rotem Tal ², Ori Goldberg ³, Yoel Levinsky ⁴, Zohar Habot-Wilner ⁵, Orly Ohana ⁶, Yulia Gendler ⁷, Liora Harel ⁸ and Gil Amarilyo⁹, ¹Schneider Children's hospital of Israel, Tel Aviv university, Petach Tikva, Israel, ²schneider medical center, Ramat Gan, Israel, ³Schneider Children's Medical Center of Israel, Tel Aviv University, Petach Tikva, Israel, ⁴Schneider Children's Medical Cnetr of Israel, Tel Aviv University, Petach Tikva, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv Univrsity, Tel Aviv, Israel, ⁶Schneider Children's Medical Cener of Israel, Petach Tikva, Israel, ⁷Schneider Children's Medical Center of Israel, Tel Aviv Univesity, Petach Tikva, Israel, ⁸Schneider Hospital, Tel Aviv University, Petah-Tiqva, Israel, ⁹Schneider Hospital, Tel Aviv University, Kibbutz Magal, Israel
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Intra-articular corticosteroids joint injection (IAJI) with Triamcinolone hexacetonide (TH) or triamcinolone acetonide…
Abstract Number: 109 • 2020 Pediatric Rheumatology Symposium
Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Mei-Sing Ong¹, Gordon Schiff ² and Marc Natter ³ for the CARRA investigators, ¹Harvard Medical School & Harvard Pilgrim Healthcare Institute, Boston, ²Harvard Medical School, Boston, ³Boston Children's Hospital, Boston
Background/Purpose: While early treatment of patients with newly diagnosed juvenile idiopathic arthritis (JIA) is an area of active study, delayed diagnosis of JIA is poorly…
Abstract Number: 179 • 2020 Pediatric Rheumatology Symposium
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Esi Morgan ², Sheetal Vora ³, Mileka Gilbert ⁴, Cagri Yildirim-Toruner ⁵, Nancy Griffin ⁶, Kerry Ferraro ⁷, Stephanie Loos ⁶, Tingting Qiu ⁶, Anne Paul ⁸, Jon Burnham ⁹, Erik Meyer ⁷, Michelle Batthish ¹⁰, Beth Gottlieb ¹¹, Danielle Bullock ¹², Melissa Hazen ¹³, Ronald Laxer ¹⁴, Tzielan Lee ¹⁵, Melissa Mannion ¹⁶, Judyann Olson ¹⁷, Michael Shishov ¹⁸, Richard Vehe ¹⁹, Jennifer Weiss ²⁰ and C. April Bingham ²¹, ¹Children's Mercy Kansas City, Overland Park, ²Cincinnati Children's Hospital, Cincinnati, ³Atrium Health Levine Children's Hospital, Charlotte, ⁴Medical University of South Carolina, Charleston, South Carolina, ⁵Nationwide Children's Hospital, Columbus, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Cincinnati Children's Hospital Medical Centre, Cincinnati, ⁹Children's Hospital of Philadelphia, Philadelphia, ¹⁰McMaster University, Hamilton, Canada, ¹¹Cohen Children's Medical Center, Lake Success, ¹²University of Minnesota, Minneapolis, ¹³Boston, ¹⁴The Hospital for Sick Children and University of Toronto, Toronto, Canada, ¹⁵Stanford Children's, Palo Alto, ¹⁶University of Alabama at Birmingham, Birmingham, ¹⁷Medical College of Wisconsin: Children's Wisconsin, Wauwatosa, Wisconsin, ¹⁸Phoenix Children's Hospital, Phoenix, ¹⁹University of Minnesota, Roseville, ²⁰Hackensack University Medical Center, Hackensack, ²¹Penn State Children's Hospital, Allentown
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning network to support pediatric rheumatology centers in improving care delivery and patient…
Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Alexandra Munroe¹, Adam Huber ², Bianca Lang ³, Suzanne Ramsey ⁴ and Elizabeth Stringer ⁴, ¹Dalhousie University, Halifax, Nova Scotia, Canada, ²IWK Health Centre & Dalhousie University, Halifax, Nova Scotia, Canada, ³Dalhousie University - Halifax, Halifax, Canada, ⁴IWK Health Centre, Halifax, Canada
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…
Abstract Number: 110 • 2020 Pediatric Rheumatology Symposium
Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort
Tara McGrath¹, Jaime Guzman ², Lori Tucker ³, Natalie Shiff ⁴, Maryna Yaskina ⁵, Susan Tupper ⁶ and Dax Rumsey ⁷, ¹University of British Columbia, Vancouver, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, Canada, ³BC Children's Hospital, Vancouver, British Columbia, Canada, ⁴Florida, Gainesville, ⁵Women and Children's Research Institute, Edmonton, Canada, ⁶Saskatoon, Canada, ⁷University of Alberta, Edmonton, Canada
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease of childhood. Pain is a distressing and prevalent feature of JIA and can decrease…
Abstract Number: 181 • 2020 Pediatric Rheumatology Symposium
Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis
Sabrina Cavallo¹, ¹University of Montreal, Montreal, Canada
Background/Purpose: The transition to adulthood for young people with juvenile idiopathic arthritis (JIA) can be difficult and lead to undesirable outcomes in terms of socio-professional…
Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Sara Concha¹, Pamela Morales ², Eduardo Talesnik ¹ and Arturo Borzutzky ¹, ¹Department of Infectious Diseases and Pediatric Immunology, School of Medicine, Pontificia Universidad Católica de Chile., Santiago, Chile, ²Department of Pediatric, Clinica Las Condes, Santiago, Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…
Abstract Number: 115 • 2020 Pediatric Rheumatology Symposium
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
Kimberly Lewis¹, Nico Osier ², Patricia Carter ³, Christina Nguyen ⁴, Ruy Carrasco ⁵, Shelby Brooks ², Alexandra Garcia ⁶ and Stefano Tiziani ⁵, ¹The University of Texas at Austin, Austin, Texas, ²The University of Texas at Austin, Austin, ³University of Alabama, Tuscalossa, ⁴Ascension Seton Nursing Research, Austin, ⁵The University of Texas at Austin, Dell Medical School, Austin, ⁶The University of Texas at Austin, Dell Medical School, School of Nursing, Austin
Background/Purpose: The purpose of this study is to define the relationships between pain and carbohydrate metabolism in teens with active juvenile idiopathic arthritis (JIA), teens…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.